Which Breast Cancer Patients will Benefit from Chemotherapy?

While no two breast cancer patients — or their tumors — are alike, there is only one predictive genomic test to help doctors prescribe individualized treatment with definitive information about the benefit of chemotherapy. The test, which is covered by Medicare and most private health insurance providers, can help patients with early-stage breast cancer determine if they are among the approximately 70,000 women each year who can avoid chemotherapy and its unnecessary side effects while still receiving effective treatment.

_____________________________________________________

(BPT) — New results from the largest ever clinical study of early-stage breast cancer patients are changing the game when it comes to who should receive chemotherapy treatment.

The study, called TAILORx (Trial Assigning Individualized Options for Treatment (Rx)), used the Oncotype DX Breast Recurrence Score® genomic test to determine exactly who will benefit from treatment with chemotherapy. Approximately 260,000 women are diagnosed with early-stage breast cancer each year in the U.S., and each of them must decide if chemotherapy is necessary to treat their disease or if they can be effectively treated with hormone therapy alone.